CABA Key Statistics, Chart & Performance
The current stock price of CABA is 3.18 USD. In the past month the price increased by 45.87%. In the past year, price increased by 27.2%.
CABA Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to CABA. When comparing the yearly performance of all stocks, CABA is one of the better performing stocks in the market, outperforming 86.79% of all stocks.
CABA Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to CABA. Both the profitability and financial health of CABA have multiple concerns.
CABA Financial Highlights
Over the last trailing twelve months CABA reported a non-GAAP Earnings per Share(EPS) of -2.53. The EPS decreased by -17.67% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -83.54% | ||
| ROE | -113.66% | ||
| Debt/Equity | 0.03 |
CABA Forecast & Estimates
16 analysts have analysed CABA and the average price target is 13.39 USD. This implies a price increase of 320.99% is expected in the next year compared to the current price of 3.18.
CABA Ownership
CABA Latest News, Press Relases and Analysis
About CABA
Company Profile
Cabaletta Bio, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. The company is headquartered in Philadelphia, Pennsylvania and currently employs 148 full-time employees. The company went IPO on 2019-10-25. Its Cabaletta Approach to B cell Ablation (CABA) platform encompasses two strategies: Chimeric Antigen Receptor T cells for Autoimmunity (CARTA) and Chimeric AutoAntibody Receptor T cells (CAART). Resecabtagene autoleucel, its lead product candidate from its CARTA platform, is a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T construct designed to treat patients with a range of autoimmune diseases. Its DSG3-CAART product candidate is being evaluated for the treatment of mPV, a subtype of PV that affects the epithelium of the mucous membranes, in the Phase 1 DesCAARTes TM trial. Its MuSK-CAART product candidate is designed to treat a subset of patients with MG, targeting autoreactive B cells.
Company Info
CABALETTA BIO INC
2929 Arch Street, Suite 600
PHILADELPHIA PENNSYLVANIA 19104 US
CEO: Steven Nichtberger
Employees: 148
Phone: 12677593100
CABALETTA BIO INC / CABA FAQ
What does CABALETTA BIO INC do?
Cabaletta Bio, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. The company is headquartered in Philadelphia, Pennsylvania and currently employs 148 full-time employees. The company went IPO on 2019-10-25. Its Cabaletta Approach to B cell Ablation (CABA) platform encompasses two strategies: Chimeric Antigen Receptor T cells for Autoimmunity (CARTA) and Chimeric AutoAntibody Receptor T cells (CAART). Resecabtagene autoleucel, its lead product candidate from its CARTA platform, is a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T construct designed to treat patients with a range of autoimmune diseases. Its DSG3-CAART product candidate is being evaluated for the treatment of mPV, a subtype of PV that affects the epithelium of the mucous membranes, in the Phase 1 DesCAARTes TM trial. Its MuSK-CAART product candidate is designed to treat a subset of patients with MG, targeting autoreactive B cells.
What is the stock price of CABALETTA BIO INC today?
The current stock price of CABA is 3.18 USD. The price increased by 8.16% in the last trading session.
Does CABALETTA BIO INC pay dividends?
CABA does not pay a dividend.
What is the ChartMill rating of CABALETTA BIO INC stock?
CABA has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Which stock exchange lists CABA stock?
CABA stock is listed on the Nasdaq exchange.
What is the Short Interest ratio of CABALETTA BIO INC (CABA) stock?
The outstanding short interest for CABALETTA BIO INC (CABA) is 19.84% of its float.